<code id='EB3D4B0815'></code><style id='EB3D4B0815'></style>
    • <acronym id='EB3D4B0815'></acronym>
      <center id='EB3D4B0815'><center id='EB3D4B0815'><tfoot id='EB3D4B0815'></tfoot></center><abbr id='EB3D4B0815'><dir id='EB3D4B0815'><tfoot id='EB3D4B0815'></tfoot><noframes id='EB3D4B0815'>

    • <optgroup id='EB3D4B0815'><strike id='EB3D4B0815'><sup id='EB3D4B0815'></sup></strike><code id='EB3D4B0815'></code></optgroup>
        1. <b id='EB3D4B0815'><label id='EB3D4B0815'><select id='EB3D4B0815'><dt id='EB3D4B0815'><span id='EB3D4B0815'></span></dt></select></label></b><u id='EB3D4B0815'></u>
          <i id='EB3D4B0815'><strike id='EB3D4B0815'><tt id='EB3D4B0815'><pre id='EB3D4B0815'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:337
          The Johnson and Johnson booth at ESMO in Madrid.
          The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

          MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

          At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

          advertisement

          In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources
          Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

          3:14InthisMarch4,2023,filephoto,formerPresidentDonaldTrumpspeakstoreportersbeforeatGaylordNationalRe

          read more
          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more

          Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

          1:03JackSmith,thentheDepartmentofJustice'schiefofthePublicIntegritySection,posesforphotoattheDepartm